Pharsight

Keppra Xr generic

Keppra Xr is an antiepileptic drug owned by Ucb Inc. Its active ingredient, levetiracetam, plays a crucial role in its action. This drug was first authorized for market use on September 12, 2008. Keppra Xr is available in tablet, extended release; oral dosage forms.

When will Keppra Xr generic be available?

As of now, Keppra Xr holds a patent which is due to expire on September 17, 2028. Following this date, it's highly likely that generic versions of Keppra Xr will be made available.

Keppra Xr uses

Keppra Xr, possessing the vital active ingredient levetiracetam, is used in the treatment of epilepsy. It helps in reducing the occurrence of seizures in epilepsy patients.

Keppra Xr patent expiration

Currently, Ucb Inc. holds a patent for Keppra Xr that is set to expire on September 17, 2028. This is important to know for those waiting for Keppra Xr generic availability. Below are the details of the patent:

Keppra Xr dosage

Want to ask something?